Phibro Animal Health Maintains FY2027 Adjusted EPS Outlook at $3.41-$3.59

• Phibro Animal Health maintained fiscal 2027 net sales guidance of $1.55 billion to $1.6 billion on November 5, 2026.
• Adjusted EBITDA is forecast at $258 million to $268 million.
• Adjusted EPS guidance remains $3.41 to $3.59; GAAP EPS is projected at $2.98 to $3.22.
• First-quarter sales rose 6% to $386.8 million; adjusted EBITDA increased 4% to $64.3 million.
• The outlook assumes no additional virginiamycin sales in Brazil following the transition period's expiration at the end of October.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phibro Animal Health Corporation published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.